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Introduction: To compare statin initiation and treatment non-adherence following a first acute myocardial
infarction (MI) in patients with inflammatory rheumatic disease (IRD) and the general population.
Methods: We conducted a retrospective cohort study using a population-based linked database. Cases of first MI
from July 2001 to June 2009 were identified based on International Classification of Diseases (ICD-10-AM) codes.
Statin initiation and adherence was identified based on pharmaceutical claims records. Logistic regression was used
to assess the odds of statin initiation by IRD status. Non-adherence was assessed as the time to first treatment gap
using a Cox proportional hazards model.
Results: There were 18,518 individuals with an index MI over the time period surviving longer than 30 days, of
whom 415 (2.2%) were IRD patients. The adjusted odds of receiving a statin by IRD status was significantly lower
(OR =0.69, 95% CI: 0.55 to 0.86) compared to the general population. No association between IRD status and statin
non-adherence was identified (hazard ratio (HR) =1.12, 95% CI: 0.82 to 1.52).
Conclusions: Statin initiation was significantly lower for people with IRD conditions compared to the general
population. Once initiated on statins, the proportion of IRD patients who adhered to treatment was similar to the
general population. Given the burden of cardiovascular disease and excess mortality in IRD patients, encouraging
the use of evidence-based therapies is critical for ensuring the best outcomes in this high risk group.Introduction
People with inflammatory rheumatic diseases (IRD), in-
cluding rheumatoid arthritis (RA), systemic lupus erythe-
matosus (SLE), systemic sclerosis (SSc), spondyloarthritis
(SpA), vasculitis and other chronic inflammatory diseases
of the connective tissues, are known to have increased car-
diovascular mortality and morbidity compared to the gen-
eral population [1-9]. This phenomenon is thought to be
related to chronic systemic inflammation that underlies
the progression of typical atherosclerotic disease and may
be accelerated in IRD sub-types [10]. Following a myocar-
dial infarction (MI), RA patients have been shown to have
increased fatality rates, with adjusted odds (ORs) ranging* Correspondence: megan.bohensky@unimelb.edu.au
1Melbourne EpiCentre, Department of Medicine, Royal Melbourne Hospital,
Level 7 E Block, Parkville, VIC 3050, Australia
Full list of author information is available at the end of the article
© 2014 Bohensky et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.from 1.2 to 3.0 [11-13]. More recently, we have shown
that IRD patients experiencing a first myocardial infarc-
tion (MI) have significantly increased adjusted odds of
death at 30 days (OR 1.51, 95% CI 1.24, 1.84) when com-
pared to the general population [14]. The majority of
deaths were found to be due to cardiovascular causes.
Clinical trials have demonstrated the efficacy of sec-
ondary pharmacological prevention strategies for reducing
cardiovascular morbidity and mortality in the general
population [15-18]. Based on this evidence, current guide-
lines advocate the use of secondary prevention medications
(anti-thrombotic therapy, oral beta-blockers, angiotensin-
converting-enzyme (ACE) inhibitor and statins) following
acute MI, where such therapy is not contra-indicated
[19-21]. Despite this evidence, our previous research sug-
gests that RA patients receive sub-optimal pharmacother-
apy after an MI. In a detailed review of the medical recordsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ment with β-blockers (OR 0.42, 95% CI 0.18, 0.96) and sta-
tins (OR 0.21, 95% CI 0.09, 0.46) to be significantly lower
than matched controls without RA at discharge [22]. The
reasons for differential treatment were not accounted for
by contraindication to therapy in RA patients. As the study
included only three hospitals (two tertiary public hospitals
and one large metropolitan private hospital in Victoria,
Australia) and was focused on in-hospital treatment only,
it is unknown if these findings are generalisable to other
settings. Subsequently Lindharsen et al conducted a
population-based study of national registries in Denmark,
which included 877 patients with RA after a first MI. They
found RA patients had significantly lower odds of treat-
ment with aspirin (OR 0.80, 95% CI:0.67, 0.96), β-blockers
(OR 0.77, 95% CI 0.65, 0.92) and statins (OR 0.69, 95% CI
0.58, 0.82) [23].
As the therapeutic benefit of secondary pharmacological
prevention therapies requires adherence, discontinuing
treatment can have serious repercussions on patient out-
comes. RA patients in one study had adherence rates of
45.4% to statin therapies over a 4-year period [24] with
poor adherence increasing the risk of MI by 2% for each
1-month increase in the duration of non-adherence [25].
Poor adherence was also found to be associated with a
significantly increased risk of cardiovascular mortality
(hazard ratio (HR) 1.60, 95% CI 1.15, 2.23) and all-cause
mortality (HR 1.79, 95% CI 1.46, 2.20) compared to RA
patients who adhered to treatment [24].
Data on pharmacotherapy initiation and adherence are
lacking for patients with IRD sub-types other than RA.
Given the known burden of cardiovascular disease, mor-
tality and increased fatality following an MI in IRD [14],
the primary aim of the present study was to compare
initiation and non-adherence to statin treatment follow-
ing a first acute MI in patients with IRD, when com-
pared to the general population.
Methods
Data sources
We used the Western Australian Data Linkage System
(WADLS) to undertake this study. WADLS uses prob-
abilistic data linkage methods to create and maintain a
dynamic set of linkages across 30 administrative health
datasets, including public and private hospital morbidity
data, pharmaceutical claims records and death data [26].
As these data are administrative in nature, there are no
missing data items. An evaluation of the WADLS link-
age has shown that the probabilistic matching algorithm
based on patient names and other partial identifiers has
99.9% sensitivity [26]. Information on patient diagnoses
and procedures for each hospital episode are coded ac-
cording to the International Statistical Classification of
Diseases and Related Health Problems, 10th Revision,Australian Modification [27] (ICD-10-AM) beginning 1
July 1998 and ICD version 9, Canadian Modification
(ICD-9-CM) prior to 1 July 1998. Pharmaceutical claims
records were obtained from the Australian Pharmaceut-
ical Benefits Scheme (PBS), which holds information on
all subsidised prescription medicines provided in the
outpatient setting [28].
Definition of index MI and IRD
All cases of MI from 1 July 2001 to 30 June 2009 were
identified based on the ICD-10-AM classifications (see
Additional file 1 for a list of all codes used to undertake
data analyses). An individual was considered to have ex-
perienced a first acute MI if they had a diagnosis of MI
within this time period and no diagnosis of MI in the
previous five years (that is, the dataset has records back
to 1 July 1996 to provide a five-year look-back period).
Our rationale for selecting a five-year look-back period
has been described previously [29].
For the purposes of this study, IRD included the follow-
ing diagnoses: RA, SLE, psoriatic arthritis (PsA), ankylos-
ing spondylitis (AS), enteropathic arthritis (EA), systemic
sclerosis (SSc), systemic vasculitis (SV), Sjogren’s syn-
drome (SjS), polymyalgia rheumatica (PMR), mixed con-
nective tissue disease (MCTD), dermatomyositis (DM)
and polymyositis (PM). Each of these conditions was con-
sidered to be present when the relevant ICD-9-CM or
ICD-10-AM diagnosis codes (see Additional file 1) were
recorded during the index MI admission or during any
hospital admission in the 5 years prior to the index MI.
We also examined the spondyloarthritis group, which
comprised AS, PsA and EA. Some patients were found to
have multiple recorded IRD conditions (n =80). These pa-
tients were counted only once in the primary analysis, but
may have contributed data to more than one subgroup in
the IRD subgroup analysis.
Outcomes
Our outcomes were statin initiation and non-adherence.
We chose to focus primarily on statins, as these are one of
the most commonly used secondary prevention pharma-
cological therapies following MI in Australia [30].
As PBS records were provided in a month-year format,
statin initiation was defined as having a statin dispensed
(including atorvastatin, fluvastatin, pravastatin, rosuvas-
tatin and simvastatin) within the month after the hos-
pital separation for the MI. We excluded patients who
died within 30 days of their hospital separation involving
the MI (n =2,608, 12.3%), as we could not determine
whether they had received a supply of statins in hospital.
As prescribing behaviour may vary depending on whether
a patient had received statins previously, we also con-
ducted a stratified analysis of initiation to examine those
patients who had a statin script prior to their MI (prior
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(statin-naïve patients).
For the assessment of non-adherence, we only con-
sidered those patients who were initiated on statins.
Non-adherence was defined as having a gap between
prescriptions exceeding three consecutive months dur-
ing the follow-up period. This definition was based
on the refill-sequence model of persistence, which has
been described previously [31]. In our dataset, prescrip-
tion dates were provided in a month-year format, there-
fore we permitted up to a 3-month gap in prescriptions to
make allowances for people who may have filled a script
at the end of one month, did not fill a script in the next
month, but then did fill their next script at the beginning
of the subsequent month (for example, completed a script
in January and refilled in March).
Statistical analysis
Descriptive statistics were used to describe the differ-
ences in the patient population for IRD patients com-
pared with non-IRD patients. Potential predictors of
statin initiation, non-adherence and mortality were con-
sidered in the descriptive analysis and time-to-event ana-
lysis. These covariates included age, gender, marital and
indigenous status, socio-economic status, proximity to
goods and services, use of statins prior to index MI, and
comorbidities of interest (predominantly based on the
Charlson comorbidity algorithm [32,33]). All covariates
were binary. Age was initially considered as a continuous
variable and then as a variable with five levels (that is,
<50, 50 to 59, 60 to 69, 70 to 79 and ≥80 years).
The chi-squared test was used to identify significant
differences between IRD and non-IRD patients for binary
or categorical variables, the Fisher exact test was used
where any cell values were under five, and the Mann-
Whitney test was used to test for differences for continu-
ous variables that were not normally distributed (that is,
length of stay). Significance was set at P <0.05.
Statin initiation was assessed using a multivariate logis-
tic regression analysis with adjustment for significant fac-
tors. Given the potential gain in efficiency of matching
cases to controls, a sensitivity analysis was undertaken to
explore this strategy. Non-IRD controls were matched to
IRD cases on age and gender in a 5-to-1 ratio. Statin non-
adherence was assessed as a competing-risk Cox propor-
tional hazards model with death as the competing risk to
statin non-adherence and time since index MI as the entry
point into the model. Time-to-event analysis was censored
at the last possible follow-up date of 30 June 2010.
Statistical analysis was performed using Stata version
12 (StataCorp LP, Texas, USA). The study was approved
by the Melbourne Health Research Ethics Committee. As
researchers accessed de-identified data only, patient con-
sent was not considered necessary.Results
Statin initiation
There were 18,518 individuals with an index MI who sur-
vived longer than 30 days, of whom 415 (2.2%) were iden-
tified as IRD patients (Figure 1). Of these, there were 207
(49.9%) IRD patients initiated on statins compared to
11,893 (65.7%) non-IRD patients, which was a significantly
different proportion (P <0.01) (Table 1). An additional file
includes P-values for Table 1 (see Additional file 2).
Within the IRD group, patients initiated on statins
were significantly more likely to be aged under 70 years,
male, have received statins in the month prior to MI,
have hypercholesterolaemia or be obese, but were less
likely to be indigenous or have certain comorbidities, in-
cluding dementia, peptic ulcer disease and pulmonary
disease when compared to patients not initiated on sta-
tins. IRD patients initiated on statins also received a
significantly higher median number of medications at
1 month post MI than patients not initiated on statins.
After adjustment for age, gender, socio-economic status,
geographic location and relevant co-morbidities, the odds
of IRD patients receiving a statin were significantly re-
duced at 0.67 (95% CI 0.54, 0.84). As cardiovascular risk
factors are known to be under-reported in administrative
data [34], we conducted a sensitivity analysis where all car-
diovascular risk factor variables (hypercholesterolaemia,
arrhythmia, obesity, hypertension and smoking) were re-
moved from the statin initiation multivariate analysis. We
identified very little change in the primary outcome (OR
0.65, 95% CI 0.52 to 0.81, P-value <0.001 from the esti-
mated OR 0.67, 95% CI 0.54 to 0.84, P-value =0.001). We
retained cardiovascular risk factors in the final model as
the standard error for the IRD variable in the model with-
out risk factors was increased. In our additional sensitivity
analysis, where IRD patients were matched on a 1:5 ratio
with non-IRD patients, the OR for IRD patients receiving
a statin was 0.72 (95% CI 0.56, 0.92, P-value =0.008) indi-
cating little change in the log odds of statin initiation.
Statin initiation by IRD sub-type is reported in Table 2.
Individuals with SpA (OR 0.43, 95% CI 0.26, 0.70), SV
(OR 0.44, 95% CI 0.20, 0.94) and SLE (OR 0.24, 95% CI
0.11, 0.59) had significantly lower adjusted odds of being
initiated on a statin compared to people without IRD.
Apart from SjS, the adjusted ORs for all other IRD sub-
types were <1.0 but were not statistically significant.
Given that there can be a delay in the uptake of guidelines,
we also examined statin initiation over two time periods.
Statin initiation increased in the period from 1 July 2004
to 30 June 2009 compared to the period from 1 July 2002
to 30 June 2004. After adjusting for significant factors, the
OR for statin initiation among IRD patients in the first
period (from 1 July 2002 to 30 June 2004) was 0.64, 95%
CI 0.45, 0.91) and in the latter period (1 July 2004 to 30
June 2009) it was 0.72, 95% CI 0.53, 0.98).
Figure 1 Flowchart of patient inclusion for inflammatory rheumatic disease (IRD) and non-IRD patients with an index myocardial
infarction (MI) from 1 July 2001 to 30 June 2009.
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tients with at least one statin prescription prior to their
MI. In our stratified analysis, the odds of statin initiation
in statin naïve IRD patients was significantly reduced
(OR =0.64, 95% CI 0.50 to 0.81). For those who used sta-
tins priors to their MI, the estimated odds for continued
statin use was not significantly different (P =0.578) in
the IRD group compared to the non-IRD group (OR 1.28,
95% CI 0.53, 3.07).
Statin non-adherence
The rate of statin non-adherence within 12 months
post-MI for patients with IRD was 20.7% compared to
14.7% for patients without IRD (P =0.02). However, this
includes patients who died over the follow-up period
and the mortality rate was higher for the IRD group
(13.0% compared to 6.0% for the non-IRD group, P <0.01).
After adjusting for age, gender, marital status, indigenous
status, socio-economic status, proximity to goods and ser-
vices, prior use of statins, relevant comorbidities andaccounting for death as a competing risk, no association
between IRD and statin non-adherence was identified (HR
1.11, 95% CI 0.82, 1.52, Table 3). No significant associa-
tions were identified between statin non-adherence and
IRD sub-type.
Discussion
In a cohort of 21,126 people experiencing a first MI over
an eight-year period, including 382 people with IRD, we
found approximately 50% of IRD patients were not initi-
ated on statins within the first month following MI. This
translates to an adjusted OR of 0.67. Among patients
who were initiated on statins, the proportion of patients
who adhered to treatment was very good (80%) and not
significantly different from the general population, after
accounting for the higher mortality in IRD patients. Given
the high burden of cardiovascular disease and mortality in
IRD patients, ensuring the prompt initiation and continu-
ation of evidence-based therapies is critical for ensuring
the best outcomes.
Table 1 Inflammatory rheumatic disease (IRD) and non-IRD patients by statin initiation
Variable IRD patients (n =415) Non-IRD patients (n =18,103)
Statins initiated Statins not initiated Statins initiated Statins not initiated
n % n % n % n %
Number of patients 207 100 208 100 11,893 100 6,210 100
Age, years
<50 9 4.4 12 5.8 1,445 12.2 613 9.9
50 to 59 32 15.5 18 8.7 2,368 19.9 804 12.9
60 to 69 38 18.4 21 10.1 2,748 23.1 947 15.3
70 to 79 77 37.2 60 28.9 3,085 25.9 1,367 22.0
80+ 51 24.6 97 46.6 2,247 18.9 2,479 39.9
Female 112 54.1 149 71.6 3,853 32.4 2,784 44.8
Indigenous 1 0.5 7 3.4 338 2.8 376 6.1
Married/de-facto 117 56.5 93 44.7 7,888 66.3 3,188 51.3
High accessibility to services1 164 79.2 164 78.8 8,500 71.5 4,390 70.7
Accessibility/Remoteness Index of
Australia (ARIA) - remote2
6 2.9 10 4.8 478 4.0 410 6.6
Lowest quartile of Socio-Economic
Indexes for Areas Index of Relative
Socio-Economic Disadvantage (SEIFA-IRSD)
11 5.3 16 7.7 805 6.8 547 8.8
Length of stay, median (IQR) 8 (5 to 16) 17 (7 to 42) 5 (4 to 10) 9 (5 to 24)
Statin use within 1 month prior to index MI 60 29.0 6 2.9 3,090 26.0 369 5.9
Comorbidities at index admission3
Cancer 12 5.7 8 3.9 340 2.9 550 8.9
Cerebral vascular accident 6 2.9 14 6.7 376 3.2 435 7.0
Dementia 3 1.4 11 5.3 108 0.9 183 2.9
Diabetes 35 16.9 45 21.7 1,803 15.2 1,194 19.2
Liver disease 0 0.0 3 1.5 18 0.2 63 1.0
Paraplegia 3 1.4 7 3.4 153 1.3 227 3.7
Peptic ulcer 3 1.4 10 4.8 110 0.9 110 1.8
Pulmonary disease 19 9.2 38 18.3 586 4.9 651 10.5
Peripheral vascular disease 3 1.4 6 2.9 274 2.3 202 3.3
Renal Disease 29 14.0 32 15.4 882 7.4 788 12.7
Cardiovascular risk factors
Smoker 40 19.3 30 14.4 3,071 25.8 1,244 20.0
Hypertension 109 52.7 97 46.6 6,299 53.0 2,825 45.5
Hypercholesterolaemia 57 27.5 15 7.2 3,873 32.6 1,165 18.8
Arrhythmia 58 28.0 71 34.1 2,584 21.7 1,849 29.8
Obesity 16 7.7 7 3.4 865 7.3 313 5.0
Procedure, during admission
PTCA 45 21.7 20 9.6 3,358 28.2 679 10.9
CABG 4 1.9 4 1.9 570 4.8 159 2.6
Count of medications at 1 months post MI, median (IQR) 7 (4 to 10) 3 (0 to 7) 4 (2 to 7) 0 (0 to 4)
Results are presented as number (n) and percent (%) unless stated otherwise. 1Based on ARIA code =1, major cities, highly accessible. 2Based on ARIA code = 4
(remote) and ARIA code = 5 (very remote). 3Based on Charlson comorbidity components and other risk factors. MI, myocardial infarction; CABG, coronary artery
bypass graft; PTCA, percutaneous transluminal coronary angioplasty.
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Table 2 Crude and adjusted odds ratios (ORs) for statin initiation by inflammatory rheumatic disease (IRD) sub-type
Condition Count Crude OR Adjusted OR
Rheumatoid arthritis 235 0.58 (0.45 to 0.75) 0.78 (0.58 to 1.05)
Polymyalgia rheumatica 59 0.38 (0.23 to 0.64) 0.73 (0.41 to 1.29)
Spondyloarthritis 84 0.41 (0.27 to 0.63) 0.43 (0.26 to 0.70)
Ankylosing spondylitis 19 0.72 (0.29 to 1.79) 0.54 (0.19 to 1.52)
Psoriatic arthropathies 64 0.36 (0.22 to 0.59) 0.42 (0.24 to 0.73)
Enteropathic arthropathies 1 - -
Systemic necrotising vascultis 37 0.32 (0.16 to 0.62) 0.44 (0.20 to 0.94)
Systemic lupus erythematosus 34 0.22 (0.10 to 0.46) 0.24 (0.11 to 0.59)
Systemic sclerosis 29 0.56 (0.27 to 1.16) 0.44 (0.20 to 1.01)
Sjogren’s syndrome 10 2.09 (0.44 to 9.84) 4.08 (0.64 to 26.04)
Dermatomyositis and polymyositis 5 0.78 (0.13 to 4.69) 0.86 (0.11 to 7.04)
Mixed Connective Tissue Disease 6 0.26 (0.05 to 1.43) 0.20 (0.03 to 1.52)
Total inflammatory rheumatic diseases 415 0.52 (0.43 to 0.63) 0.67 (0.54 to 0.84)
Adjusted ORs were adjusted for age, gender, socio-economic status, geographic location and relevant co-morbidities. For sub-type, 80 patients had multiple (>1)
IRD diagnoses but were counted only once in the primary analysis. Bolded text indicates statistically significant factors (P <0.05).
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in IRD patients may be the non-traditional presentation
of cardiovascular (CV) risk in this group. IRD patients
who were already receiving statins prior to their AMI
did not have significantly lower rates of continuation
when compared to non-IRD patients. This suggests that
the issue with statin initiation relates to identifying and
treating statin-naïve IRD patients. Previous guidelines
have recommended statin treatment be initiated after
MI only when total cholesterol is greater than 5 mmol/l
[35]. Changes to guidelines and practice started to occur
in the early 2000s when statin use was recommended re-
gardless of lipid levels [36], but it may have taken several
years for this recommendation to gain widespread adop-
tion by clinicians.
Patients with SLE, SV and SpA were found to re-
ceive less statin treatment compared to the other IRD
groups. These patients are known to have a two- to
three-fold risk of CV mortality compared to the gen-
eral population and this risk may be further increased
in the presence of traditional CV risk factors [37-39].
Statin therapy is recommended due to its lipid-
lowering properties and anti-inflammatory effects
[37,40]. However, several reports in the literature have
suggested that long-term statin exposure may trigger
or aggravate autoimmune diseases, particularly SLE,
due to immunomodulatory effects [41]. While the evi-
dence for a causal relationship between statin use and
SLE is not well-established, it is unclear if clinicians
are hesitant to initiate statin therapy in SLE patients
due to this concern. There was also a higher propor-
tion of indigenous Australians in the SLE group
(17.7%) [42], and disparities in statin treatment for indigen-
ous populations have been noted previously [43]. A recentstudy has shown that classic CV risk scores underestimate
the risk for patients with PsA when compared with ultra-
sound assessment of carotid intima thickness, which may
contribute to under-treatment in this population [44].
Given the heightened risk of CV disease morbidity and
mortality in patients with SLE, SV and SpA, further re-
search is required to understand barriers to statin initiation
in these populations.
In their study of initiation and adherence to secondary
prevention pharmacotherapies, Linhdardsen et al. found
RA patients in Denmark were less likely to be initiated
on and adhere to statin therapies following MI [23].
These authors also suggest the added clinical complexity
of RA may discourage clinicians from initiating statin
treatment, which carries risks of myopathy, rhabdomyoly-
sis, and hepatotoxicity. We also identified lower rates of
statin adherence among our IRD cohort, but this was not
statistically significant, which may relate to our smaller
sample size or to social differences between Denmark and
Australia. While prescription of lipid-lowering agents was
79% less (OR 0.21, 95% CI 0.09, 0.46) in our previous
study of RA patients over the period from 1995 to 2005
[22], in the present study we found prescription of statins
to be 33% lower in IRD patients over the period from
2001 to 2009. Although our data were taken from a differ-
ent state in Australia, this observation could suggest chan-
ging practice over time, as we identified an increasing
trend in statin initiation for IRD patients by time period.
This trend may coincide with guidelines on the manage-
ment of acute coronary syndrome published by the
Australian National Heart Foundation in 2006, which
recommend the use of medications at discharge, includ-
ing statins, in long-term management after control of
the MI [20].
Table 3 Factors associated with the rate of statin
non-adherence (n =12,100)
Hazard ratio 95% CI P-value
Inflammatory rheumatic
disease
1.11 0.82, 1.52 0.49
Age group, years
<50 1 - -
50 to 59 0.80 0.72, 0.89 <0.001
60 to 69 0.67 0.59, 0.75 <0.001
70 to 79 0.58 0.51, 0.66 <0.001
80+ 0.49 0.42, 0.58 <0.001
Female 0.97 0.89, 1.06 0.49
Indigenous 2.01 1.69, 2.41 <0.001
Married/de-facto 0.91 0.84, 0.99 0.03
Remote1 1.02 0.86, 1.22 0.86
Lowest quartile of
Socio-Economic Indexes for Areas
Index of Relative Socio-Economic
Disadvantage (SEIFA-IRSD)
1.12 0.97, 1.30 0.12
Elective admission 0.87 0.75, 1.01 0.06
Intensive Care Unit during
admission
0.98 0.87, 1.09 0.65
Hospital type
Tertiary 1 - -
Public metro 0.92 0.65, 1.31 0.64
Rural public/private 0.88 0.77, 0.99 0.04
Private metro 1.00 0.89, 1.13 0.94
Comorbidities at index
admission2
Cancer 1.09 0.77, 1.53 0.63
Cerebral vascular accident 0.80 0.58, 1.09 0.16
Dementia 1.04 0.60, 1.81 0.88
Diabetes 1.02 0.91, 1.14 0.72
HIV - - -
Liver disease 1.51 0.63, 3.63 0.36
Paraplegia 0.92 0.56, 1.53 0.76
Peptic ulcer 1.29 0.86, 1.94 0.21
Pulmonary disease 1.06 0.87, 1.29 0.57
Peripheral vascular disease 1.02 0.78, 1.35 0.87
Renal Disease 1.00 0.84, 1.19 0.96
Cardiovascular Risk factors
Smoker 1.17 1.07, 1.27 <0.001
Hypertension 1.06 0.98, 1.14 0.15
Hypercholesterolaemia 1.03 0.95, 1.11 0.54
Obesity 1.15 1.01, 1.30 0.03
Count of PBS medications
at 3 months post MI
0 to 1 1 - -
Table 3 Factors associated with the rate of statin
non-adherence (n =12,100) (Continued)
2 to 5 0.76 0.60, 0.96 0.02
6 to 10 0.70 0.55, 0.89 <0.01
>10 0.68 0.52, 0.87 <0.01
Statin use within 12 months
prior to index MI
0.90 0.82, 0.98 0.02
Analysis of factors was based on a competing risk, Cox Regression Model,
adjusting for death for all patients initiated on statins. 1Based on ARIA Code =4,
excluding those deceased within 3 months, unlimited follow-up. 2Based on
Charlson comorbidity components. Bolded text indicates statistically significant
factors (P <0.05). PBS, Pharmaceutical Benefits Scheme; MI, myocardial infarction.
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including all incident MIs within the state of Western
Australia, however there are several limitations worth
noting. It is not known if patients received statins during
their hospital admission or had a supply dispensed at the
time of discharge, as PBS records do not record hospital
drug dispensing. We also assumed that if prescriptions
were filled, then the drugs were taken, but this may not
always be so. The data on prescription dates were in a
month-year format, rather than precise dates. Therefore,
we had to make assumptions about the exact duration of
scripts and period of adherence. We accepted three
months as being an acceptable gap between scripts; how-
ever, accepting a full 90-day gap between prescriptions
may underestimate non-adherence. The study relied on
coded hospital administrative data, which were not de-
signed primarily for research purposes and may therefore
contain coding errors. While CV risk factors are known to
be under-coded in administrative data, removal of these
factors from the multivariate analysis did not change our
findings. We chose a five-year look-back period to identify
a history of previous MIs. While this may have misclassi-
fied some subsequent MIs as the first MI, an individual
who experienced an MI during the study period and had a
history of previous MI more than five years prior would
be likely to receive comparable treatment to individuals
with a true first MI [45,46]. Furthermore, this misclassifi-
cation is likely to be equal in the IRD and non-IRD groups
and therefore not introduce bias. Similarly, the coding of
IRD conditions may have inaccuracies and be biased to-
wards only coding the most severe cases. However, we
chose a three-year look-back period to capture IRD condi-
tions that may have been coded in a patient’s previous
hospital admissions. As our primary analyses examined
initiation and non-adherence in IRD patients overall, this
may lead to an over-generalisation of findings from one
rheumatic disease group to all groups. While we also
considered initiation and non-adherence among the IRD
sub-types, there was a limited sample size in some popula-
tions. The presence of multiple IRD sub-types may be due
to coding errors over time or diagnostic uncertainty. As
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noses against a secondary source of information and
exclude diagnoses due to potential misclassification.
Conclusion
Despite recent improvements in statin initiation rates, this
large population-based study found that patients with IRD
were less likely to be initiated on statin therapies following
an MI when compared to the general population. However,
once initiated, IRD patients were found to adhere to statins
at similar rates to non-IRD patients. Given the high risk of
CV disease and mortality in IRD populations, increased
rates of early initiation on statins following MI as an
effective and safe secondary preventative therapy should be
encouraged. The underlying factors driving this differential
treatment should be examined further to improve care and
outcomes of patients with IRD.
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